EVP Yann Mazabraud Sells 2,551 Shares of Rhythm Pharmaceuticals Inc
On February 13, 2024, Yann Mazabraud, EVP, Head of International at Rhythm Pharmaceuticals Inc, executed a sale of 2,551 shares of the company. The transaction was filed with the SEC and can be found through this SEC Filing.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. The company aims to transform the care of people living with rare genetic disorders of obesity by developing and delivering targeted therapies that restore the MC4R pathway, a key biological pathway in humans that regulates weight by increasing energy expenditure and reducing appetite.
Over the past year, the insider has sold a total of 3,728 shares and has not made any purchases. The recent sale by the insider is part of a broader trend observed at Rhythm Pharmaceuticals Inc, where there have been 26 insider sells and no insider buys over the past year.
On the date of the insider's recent transaction, shares of Rhythm Pharmaceuticals Inc were trading at $50.8 each, giving the company a market capitalization of approximately $2.89 billion.
The insider's activity can be an important indicator of a company's performance and prospects from the perspective of those closest to the business. However, it is also essential to consider a wide array of factors when evaluating the potential of a stock investment.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
